BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wisniewski A, Kirchgesner J, Seksik P, Landman C, Bourrier A, Nion-Larmurier I, Marteau P, Cosnes J, Sokol H, Beaugerie L;  the Saint-Antoine IBD network. Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines. United European Gastroenterol J. 2020;8:303-313. [PMID: 32529821 DOI: 10.1177/2050640619889763] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 13.3] [Reference Citation Analysis]
Number Citing Articles
1 Anjum MR, Chalmers J, Hamid R, Rajoriya N. COVID-19: Effect on gastroenterology and hepatology service provision and training: Lessons learnt and planning for the future. World J Gastroenterol 2021; 27(44): 7625-7648 [PMID: 34908803 DOI: 10.3748/wjg.v27.i44.7625] [Reference Citation Analysis]
2 Magro F, Rahier JF, Abreu C, MacMahon E, Hart A, van der Woude CJ, Gordon H, Adamina M, Viget N, Vavricka S, Kucharzik T, Leone S, Siegmund B, Danese S, Peyrin-Biroulet L. Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce. J Crohns Colitis. 2020;14:S798-S806. [PMID: 32722754 DOI: 10.1093/ecco-jcc/jjaa160] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 13.5] [Reference Citation Analysis]
3 Chebli JMF, Queiroz NSF, Damião AOMC, Chebli LA, Costa MHM, Parra RS. How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician. World J Gastroenterol 2021; 27(11): 1022-1042 [PMID: 33776370 DOI: 10.3748/wjg.v27.i11.1022] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
4 Ricciuto A, Lamb CA, Benchimol EI, Walker GJ, Kennedy NA, Kuenzig ME, Kaplan GG, Kappelman MD, Ungaro RC, Colombel JF, Brenner EJ, Agrawal M, Reinisch W, Griffiths AM, Sebastian S. Inflammatory Bowel Disease Clinical Activity Is Associated with COVID-19 Severity Especially in Younger Patients. J Crohns Colitis 2021:jjab172. [PMID: 34570886 DOI: 10.1093/ecco-jcc/jjab172] [Reference Citation Analysis]
5 Goodsall TM, Han S, Bryant RV. Understanding attitudes, concerns, and health behaviors of patients with inflammatory bowel disease during the coronavirus disease 2019 pandemic. J Gastroenterol Hepatol 2021;36:1550-5. [PMID: 33063927 DOI: 10.1111/jgh.15299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
6 Doherty J, Fennessy S, Stack R, O' Morain N, Cullen G, Ryan EJ, De Gascun C, Doherty GA. Review Article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic. Aliment Pharmacol Ther 2021;54:1110-23. [PMID: 34472643 DOI: 10.1111/apt.16590] [Reference Citation Analysis]
7 Matsumoto S, Mashima H. Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease. Sci Rep 2020;10:22176. [PMID: 33335169 DOI: 10.1038/s41598-020-79207-z] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Kennedy NA, Jones GR, Lamb CA, Appleby R, Arnott I, Beattie RM, Bloom S, Brooks AJ, Cooney R, Dart RJ, Edwards C, Fraser A, Gaya DR, Ghosh S, Greveson K, Hansen R, Hart A, Hawthorne AB, Hayee B, Limdi JK, Murray CD, Parkes GC, Parkes M, Patel K, Pollok RC, Powell N, Probert CS, Raine T, Sebastian S, Selinger C, Smith PJ, Stansfield C, Younge L, Lindsay JO, Irving PM, Lees CW. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut 2020;69:984-90. [PMID: 32303607 DOI: 10.1136/gutjnl-2020-321244] [Cited by in Crossref: 124] [Cited by in F6Publishing: 114] [Article Influence: 62.0] [Reference Citation Analysis]
9 Lees CW, Irving PM, Beaugerie L. COVID-19 and IBD drugs: should we change anything at the moment? Gut 2021;70:632-4. [PMID: 33214164 DOI: 10.1136/gutjnl-2020-323247] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Garcia KS, Moutinho BD, de Azevedo MFC, Queiroz NSF, Milani LR, Sanches LN, Barros LL, Oba J, Carlos AS, Damião AOMC, Sipahi AM. Recovery from COVID-19 Pneumonia in a Patient with Acute Severe Colitis. Inflamm Intest Dis 2020;5:93-7. [PMID: 32984404 DOI: 10.1159/000508161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Craviotto V, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, Fiorino G, Danese S, Allocca M. Viral infections in inflammatory bowel disease: Tips and tricks for correct management. World J Gastroenterol 2021; 27(27): 4276-4297 [PMID: 34366605 DOI: 10.3748/wjg.v27.i27.4276] [Reference Citation Analysis]
12 Tarris G, de Rougemont A, Charkaoui M, Michiels C, Martin L, Belliot G. Enteric Viruses and Inflammatory Bowel Disease. Viruses 2021;13:104. [PMID: 33451106 DOI: 10.3390/v13010104] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Sharma E, Meade S, D'Errico F, Pavlidis P, Luber R, Zeki S, Hill K, Duff A, O'Hanlon D, Tripoli S, Stanton A, Caracostea A, Honap S, Reynolds R, Anderson S, Ray S, Mawdsley J, Sanderson J, Samaan MA, Irving PM. The effects of COVID-19 on IBD prescribing and service provision in a UK tertiary centre. GastroHep 2020;2:318-26. [PMID: 33362435 DOI: 10.1002/ygh2.433] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
14 Drenth JP, Lerch MM. The UEG Journal is steaming ahead. United European Gastroenterol J 2020;8:1139-40. [PMID: 33276711 DOI: 10.1177/2050640620973079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Macaluso FS, Liguori G, Galli M. Vaccinations in patients with inflammatory bowel disease. Dig Liver Dis 2021:S1590-8658(21)00267-X. [PMID: 34116972 DOI: 10.1016/j.dld.2021.05.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Din S, Kent A, Pollok RC, Meade S, Kennedy NA, Arnott I, Beattie RM, Chua F, Cooney R, Dart RJ, Galloway J, Gaya DR, Ghosh S, Griffiths M, Hancock L, Hansen R, Hart A, Lamb CA, Lees CW, Limdi JK, Lindsay JO, Patel K, Powell N, Murray CD, Probert C, Raine T, Selinger C, Sebastian S, Smith PJ, Tozer P, Ustianowski A, Younge L, Samaan MA, Irving PM. Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut. 2020;69:1769-1777. [PMID: 32513653 DOI: 10.1136/gutjnl-2020-321927] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
17 Hansen R, Meade S, Beattie RM, Auth MK, Croft N, Davies P, Devadason D, Doherty C, Epstein J, Howarth L, Kiparissi F, Muhammed R, Shivamurthy V, Spray C, Stanton MP, Torrente F, Urs A, Wilson D, Irving PM, Samaan M, Kammermeier J. Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut 2021;70:1044-52. [PMID: 32873696 DOI: 10.1136/gutjnl-2020-322449] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Sebastian S, Walker GJ, Kennedy NA, Conley TE, Patel KV, Subramanian S, Kent AJ, Segal JP, Brookes MJ, Bhala N, Gonzalez HA, Hicks LC, Mehta SJ, Lamb CA;  PROTECT-ASUC Study Group. Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. Lancet Gastroenterol Hepatol. 2021;6:271-281. [PMID: 33545083 DOI: 10.1016/s2468-1253(21)00016-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
19 Maclean A, Ashton JJ, Garrick V, Beattie RM, Hansen R. Impact of COVID-19 on the diagnosis, assessment and management of children with inflammatory bowel disease in the UK: implications for practice. BMJ Paediatr Open 2020;4:e000786. [PMID: 34192173 DOI: 10.1136/bmjpo-2020-000786] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Bourgonje AR, van Linschoten RCA, West RL, van Dijk MA, van Leer-Buter CC, Kats-Ugurlu G, Pierik MJ, Festen EAM, Weersma RK, Dijkstra G. Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options. Therap Adv Gastroenterol 2021;14:17562848211012595. [PMID: 33995584 DOI: 10.1177/17562848211012595] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Farkas K, Pigniczki D, Rutka M, Szántó KJ, Resál T, Bor R, Fábián A, Szepes Z, Lázár G, Molnár T. The complex relationship between viruses and inflammatory bowel disease - review and practical advices for the daily clinical decision-making during the SARS-CoV-2 pandemic. Therap Adv Gastroenterol 2021;14:1756284820988198. [PMID: 33953797 DOI: 10.1177/1756284820988198] [Reference Citation Analysis]
22 Al-Ani AH, Prentice RE, Rentsch CA, Johnson D, Ardalan Z, Heerasing N, Garg M, Campbell S, Sasadeusz J, Macrae FA, Ng SC, Rubin DT, Christensen B. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. Aliment Pharmacol Ther 2020;52:54-72. [PMID: 32348598 DOI: 10.1111/apt.15779] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 20.0] [Reference Citation Analysis]
23 Stallmach A, Sturm A, Blumenstein I, Helwig U, Koletzko S, Lynen P, Schmidt C, Dignass A, Kucharzik T; Collaborators:. Addendum to S3-Guidelines Crohn’s disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic – open questions and answers. Z Gastroenterol 2020;58:982-1002. [DOI: 10.1055/a-1234-8079] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
24 Queiroz NSF, Barros LL, Azevedo MFC, Oba J, Sobrado CW, Carlos AS, Milani LR, Sipahi AM, Damião AOMC. Management of inflammatory bowel disease patients in the COVID-19 pandemic era: a Brazilian tertiary referral center guidance. Clinics (Sao Paulo) 2020;75:e1909. [PMID: 32321117 DOI: 10.6061/clinics/2020/e1909] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
25 Wu T, Zuo Z, Kang S, Jiang L, Luo X, Xia Z, Liu J, Xiao X, Ye M, Deng M. Multi-organ Dysfunction in Patients with COVID-19: A Systematic Review and Meta-analysis. Aging Dis 2020;11:874-94. [PMID: 32765952 DOI: 10.14336/AD.2020.0520] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
26 Segal JP, Kumar A, Raine T, Lamb CA, Brookes MJ. The impact of SARS-CoV-2 variants on IBD management. Lancet Gastroenterol Hepatol 2021;6:343-4. [PMID: 33711289 DOI: 10.1016/S2468-1253(21)00075-3] [Reference Citation Analysis]
27 Calafat M, Mañosa M, Cañete F, Domènech E. Clinical Considerations Regarding the Use of Thiopurines in Older Patients with Inflammatory Bowel Disease. Drugs Aging 2021;38:193-203. [PMID: 33438138 DOI: 10.1007/s40266-020-00832-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Gargallo-Puyuelo CJ, Laredo V, Gomollón F. Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era? Front Med (Lausanne) 2021;8:681907. [PMID: 34336887 DOI: 10.3389/fmed.2021.681907] [Reference Citation Analysis]
29 Ward D, Gørtz S, Ernst MT, Andersen NN, Kjær SK, Hallas J, Christensen S, Christiansen CF, Israelsen SB, Benfield T, Pottegård A, Jess T. The effect of immunosuppressants on the prognosis of SARS-CoV-2 infection. Eur Respir J 2021:2100769. [PMID: 34475227 DOI: 10.1183/13993003.00769-2021] [Reference Citation Analysis]
30 Viganò C, Mulinacci G, Palermo A, Barisani D, Pirola L, Fichera M, Invernizzi P, Massironi S. Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future. World J Gastroenterol 2021; 27(33): 5520-5535 [PMID: 34588749 DOI: 10.3748/wjg.v27.i33.5520] [Reference Citation Analysis]
31 Taxonera C, Sagastagoitia I, Alba C, Mañas N, Olivares D, Rey E. 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. Aliment Pharmacol Ther 2020;52:276-83. [PMID: 32359205 DOI: 10.1111/apt.15804] [Cited by in Crossref: 83] [Cited by in F6Publishing: 70] [Article Influence: 41.5] [Reference Citation Analysis]
32 Barlow-Pay F, Htut TW, Khezrian M, Myint PK. Systematic review of immunosuppressant guidelines in the COVID-19 pandemic. Ther Adv Drug Saf 2021;12:2042098620985687. [PMID: 33628418 DOI: 10.1177/2042098620985687] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
33 Izadi Z, Brenner EJ, Mahil SK, Dand N, Yiu ZZN, Yates M, Ungaro RC, Zhang X, Agrawal M, Colombel JF, Gianfrancesco MA, Hyrich KL, Strangfeld A, Carmona L, Mateus EF, Lawson-Tovey S, Klingberg E, Cuomo G, Caprioli M, Cruz-Machado AR, Mazeda Pereira AC, Hasseli R, Pfeil A, Lorenz HM, Hoyer BF, Trupin L, Rush S, Katz P, Schmajuk G, Jacobsohn L, Seet AM, Al Emadi S, Wise L, Gilbert EL, Duarte-García A, Valenzuela-Almada MO, Isnardi CA, Quintana R, Soriano ER, Hsu TY, D'Silva KM, Sparks JA, Patel NJ, Xavier RM, Marques CDL, Kakehasi AM, Flipo RM, Claudepierre P, Cantagrel A, Goupille P, Wallace ZS, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirotich E, Sufka P, Robinson PC, Machado PM, Griffiths CEM, Barker JN, Smith CH, Yazdany J, Kappelman MD; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Allianc., Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Alliance (GRA). Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Netw Open 2021;4:e2129639. [PMID: 34661663 DOI: 10.1001/jamanetworkopen.2021.29639] [Reference Citation Analysis]
34 De Lima-Karagiannis A, Juillerat P, Sebastian S, Pedersen N, Bar-Gil Shitrit A, van der Woude CJ. Management of Pregnant Inflammatory Bowel Disease Patients During the COVID-19 Pandemic. J Crohns Colitis. 2020;14:S807-S814. [PMID: 33085970 DOI: 10.1093/ecco-jcc/jjaa125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
35 Zahedi Niaki O, Anadkat MJ, Chen ST, Fox LP, Harp J, Micheletti RG, Nambudiri VE, Pasieka HB, Shinohara MM, Rosenbach M, Merola JF. Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists. J Am Acad Dermatol 2020;83:1150-9. [PMID: 32569797 DOI: 10.1016/j.jaad.2020.06.051] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
36 Łodyga M, Eder P, Dobrowolska A, Reguła J, Rydzewska G. The position statement of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology regarding the management of patients with inflammatory bowel disease during the COVID-19 pandemic. Prz Gastroenterol 2020;15:85-8. [PMID: 32550938 DOI: 10.5114/pg.2020.94544] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Spalinger MR, Hai R, Li J, Santos AN, Nordgren TM, Tremblay ML, Eckmann L, Hanson E, Scharl M, Wu X, Boland BS, McCole DF. Identification of a Novel Susceptibility Marker for SARS-CoV-2 Infection in Human Subjects and Risk Mitigation with a Clinically Approved JAK Inhibitor in Human/Mouse Cells.bioRxiv. 2020;. [PMID: 33330862 DOI: 10.1101/2020.12.09.416586] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Hadi Y, Dulai PS, Kupec J, Mohy-Ud-Din N, Jairath V, Farraye FA, Kochhar GS. Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: Propensity matched research network analysis. Aliment Pharmacol Ther 2021. [PMID: 34904240 DOI: 10.1111/apt.16730] [Reference Citation Analysis]
39 Gilissen LPL, Heinen SGH, Rijpma-Jacobs L, Schoon E, Schreuder RM, Wensing AM, van der Ende-van Loon MCM, Bloemen JG, Stapelbroek JM, Stronkhorst A. Neither inflammatory bowel disease nor immunosuppressants are associated with an increased risk of severe COVID-19: an observational Dutch cohort study. Clin Exp Med 2021. [PMID: 34542781 DOI: 10.1007/s10238-021-00755-3] [Reference Citation Analysis]
40 Noor NM, Hart AL, Irving PM, Ghosh S, Parkes M, Raine T. Clinical trials (and tribulations): the immediate effects of COVID-19 on IBD clinical research activity in the United Kingdom. J Crohns Colitis 2020:jjaa137. [PMID: 32598438 DOI: 10.1093/ecco-jcc/jjaa137] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
41 Wang H, Tu L, Li Y, Bai T, Zou K, Xiao F, Li J, Chen M, Zhang H, Li G, Lu Y, Wang K, Jin S, Yang Y, Zhu L, Hou X. The Symptoms and Medications of Patients with Inflammatory Bowel Disease in Hubei Province after COVID-19 Epidemic. J Immunol Res. 2020;2020:2847316. [PMID: 33062719 DOI: 10.1155/2020/2847316] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
42 Anikhindi SA, Kumar A, Arora A. COVID-19 in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2020;14:1187-93. [PMID: 32856955 DOI: 10.1080/17474124.2020.1816822] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
43 Scaldaferri F, Pugliese D, Privitera G, Onali S, Lopetuso LR, Rizzatti G, Settanni CR, Pizzoferrato M, Schiavoni E, Turchini L, Amatucci V, Napolitano D, Bernabei T, Mora V, Laterza L, Papa A, Guidi L, Rapaccini GL, Gasbarrini A, Armuzzi A. Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre. United European Gastroenterol J. 2020;8:775-781. [PMID: 32438878 DOI: 10.1177/2050640620929133] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
44 Magro F, Nuzzo A, Abreu C, Libânio D, Rodriguez-Lago I, Pawlak K, Hollenbach M, Brouwer WP, Siau K. COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology. United European Gastroenterol J 2021. [PMID: 34190413 DOI: 10.1002/ueg2.12115] [Reference Citation Analysis]